Publications by authors named "Kathryn L Zolman"
Article Synopsis
- A phase II trial investigated the effectiveness of combining enzalutamide with fulvestrant in treating ER+/HER2- breast cancer to see if it reduces residual tumors at surgery compared to fulvestrant alone.
- * The combination treatment showed a significantly higher rate of achieving complete tumor response (PEPI=0) and improved immune activation in tumors compared to fulvestrant only.
- * Results indicated that the combination therapy not only lowered Ki67 levels (a marker for cancer proliferation) but also altered the tumor immune environment, suggesting increased anti-tumor activity.
Metastatic breast cancer (mBC) tissue in bone was systematically profiled to define the composition of the tumor microenvironment. Gene expression identified a high myeloid signature of patients with improved survival outcomes. Bone metastases were profiled by spatial proteomics to examine myeloid populations within the stroma that correlated with macrophage functions.
View Article and Find Full Text PDFThis clinical trial combined fulvestrant with the anti-androgen enzalutamide in women with metastatic ER+/HER2- breast cancer (BC). Eligible patients were women with ECOG 0-2, ER+/HER2- measurable or evaluable metastatic BC. Prior fulvestrant was allowed.
View Article and Find Full Text PDFArticle Synopsis
- Stromal fibrosis in pancreatic ductal adenocarcinoma (PDAC) activates pathways that promote survival and epithelial-to-mesenchymal transition (EMT), contributing to resistance to therapy and tumor invasion after radiation treatment.
- Research shows that after neoadjuvant stereotactic body radiation therapy (SBRT), there is an increase in fibrosis and specific gene signatures associated with EMT, implicating two proteins—ADAM10 and ephrinB2—as key players in tumor progression.
- Targeting ADAM10 can reduce RT-induced fibrosis and enhance tumor cell sensitivity to radiation, leading to increased survival in mouse models, suggesting new strategies to overcome radiation resistance in PDAC patients.